• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤中的免疫微环境:组成部分、治疗策略及临床应用

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.

作者信息

Zhu Tianyi, Han Jing, Yang Liu, Cai Zhengdong, Sun Wei, Hua Yingqi, Xu Jing

机构信息

Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Bone Tumor Institution, Shanghai, China.

出版信息

Front Immunol. 2022 Jun 1;13:907550. doi: 10.3389/fimmu.2022.907550. eCollection 2022.

DOI:10.3389/fimmu.2022.907550
PMID:35720360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9198725/
Abstract

Osteosarcoma is a primary malignant tumor that tends to threaten children and adolescents, and the 5-year event-free survival rate has not improved significantly in the past three decades, bringing grief and economic burden to patients and society. To date, the genetic background and oncogenesis mechanisms of osteosarcoma remain unclear, impeding further research. The tumor immune microenvironment has become a recent research hot spot, providing novel but valuable insight into tumor heterogeneity and multifaceted mechanisms of tumor progression and metastasis. However, the immune microenvironment in osteosarcoma has been vigorously discussed, and the landscape of immune and non-immune component infiltration has been intensively investigated. Here, we summarize the current knowledge of the classification, features, and functions of the main infiltrating cells, complement system, and exosomes in the osteosarcoma immune microenvironment. In each section, we also highlight the complex crosstalk network among them and the corresponding potential therapeutic strategies and clinical applications to deepen our understanding of osteosarcoma and provide a reference for imminent effective therapies with reduced adverse effects.

摘要

骨肉瘤是一种主要威胁儿童和青少年的原发性恶性肿瘤,在过去三十年中,其5年无事件生存率并未显著提高,给患者和社会带来了痛苦和经济负担。迄今为止,骨肉瘤的遗传背景和致癌机制仍不清楚,这阻碍了进一步的研究。肿瘤免疫微环境已成为最近的研究热点,为肿瘤异质性以及肿瘤进展和转移的多方面机制提供了新颖且有价值的见解。然而,骨肉瘤中的免疫微环境已被广泛讨论,免疫和非免疫成分浸润的格局也已得到深入研究。在此,我们总结了骨肉瘤免疫微环境中主要浸润细胞、补体系统和外泌体的分类、特征及功能的现有知识。在每个部分中,我们还强调了它们之间复杂的相互作用网络以及相应的潜在治疗策略和临床应用,以加深我们对骨肉瘤的理解,并为即将到来的副作用减少的有效治疗提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1421/9198725/fb41b35c2aff/fimmu-13-907550-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1421/9198725/cdd753034561/fimmu-13-907550-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1421/9198725/fb41b35c2aff/fimmu-13-907550-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1421/9198725/cdd753034561/fimmu-13-907550-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1421/9198725/fb41b35c2aff/fimmu-13-907550-g002.jpg

相似文献

1
Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.骨肉瘤中的免疫微环境:组成部分、治疗策略及临床应用
Front Immunol. 2022 Jun 1;13:907550. doi: 10.3389/fimmu.2022.907550. eCollection 2022.
2
Role of exosomal miR‑21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review).外泌体 miR-21 在肿瘤微环境及骨肉瘤发生发展中的作用(综述)。
Int J Oncol. 2020 May;56(5):1055-1063. doi: 10.3892/ijo.2020.4992. Epub 2020 Feb 19.
3
Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms.解锁骨肉瘤的肿瘤免疫微环境:对免疫景观和机制的深入了解。
Front Immunol. 2024 Sep 18;15:1394284. doi: 10.3389/fimmu.2024.1394284. eCollection 2024.
4
Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs.骨肉瘤细胞来源的外泌体通过特异性包装 microRNAs 影响肿瘤微环境。
Carcinogenesis. 2020 Jul 10;41(5):666-677. doi: 10.1093/carcin/bgz130.
5
The interaction between osteosarcoma and other cells in the bone microenvironment: From mechanism to clinical applications.骨肉瘤与骨微环境中其他细胞之间的相互作用:从机制到临床应用
Front Cell Dev Biol. 2023 May 3;11:1123065. doi: 10.3389/fcell.2023.1123065. eCollection 2023.
6
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.转移性骨肉瘤中免疫排斥的途径与患者预后不良相关。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-001772.
7
Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.骨肉瘤肿瘤微环境的特征分析确定了预后和免疫治疗相关的基因特征。
J Immunol Res. 2022 Aug 27;2022:6568278. doi: 10.1155/2022/6568278. eCollection 2022.
8
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.解析肿瘤微环境在骨肉瘤进展和转移中的影响
Cancers (Basel). 2023 Oct 23;15(20):5108. doi: 10.3390/cancers15205108.
9
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?原发性骨肿瘤及其微环境中 Wnt/β-连环蛋白信号通路的新见解:开发治疗策略的有前途靶点?
Int J Mol Sci. 2019 Jul 31;20(15):3751. doi: 10.3390/ijms20153751.
10
Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.基因表达分类器揭示了预后骨肉瘤微环境的分子亚型。
Front Immunol. 2021 Apr 20;12:623762. doi: 10.3389/fimmu.2021.623762. eCollection 2021.

引用本文的文献

1
Molecular and Glycosylation Pathways in Osteosarcoma: Tumor Microenvironment and Emerging Strategies Toward Personalized Oncology.骨肉瘤中的分子和糖基化途径:肿瘤微环境与个性化肿瘤学的新兴策略
Curr Issues Mol Biol. 2025 Aug 7;47(8):629. doi: 10.3390/cimb47080629.
2
Hino-Fe Chelate Suppresses Osteosarcoma Progression through Dual Induction of Ferroptosis and NLRC4-mediated Pyroptosis: Mechanisms and Therapeutic Implications.日野铁螯合物通过双重诱导铁死亡和NLRC4介导的细胞焦亡抑制骨肉瘤进展:机制与治疗意义
Int J Biol Sci. 2025 Jul 28;21(11):4872-4894. doi: 10.7150/ijbs.113785. eCollection 2025.
3
Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells.

本文引用的文献

1
Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?骨肿瘤细胞外囊泡:拮抗剂还是治疗剂?
Int J Mol Sci. 2021 Nov 22;22(22):12586. doi: 10.3390/ijms222212586.
2
Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma.骨肉瘤的细胞分化轨迹相关分子分类。
Genes (Basel). 2021 Oct 23;12(11):1685. doi: 10.3390/genes12111685.
3
Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases.超越免疫抑制作用:髓系来源的抑制性细胞在骨相关疾病中的双重作用。
用于骨肉瘤低温光热-光动力-化学动力疗法的免疫调节双靶点纳米材料,靶向肿瘤细胞和内皮细胞
ACS Nano. 2025 Sep 2;19(34):30786-30809. doi: 10.1021/acsnano.5c00223. Epub 2025 Aug 20.
4
Immunosuppressive Tumor Microenvironment of Osteosarcoma.骨肉瘤的免疫抑制性肿瘤微环境
Cancers (Basel). 2025 Jun 24;17(13):2117. doi: 10.3390/cancers17132117.
5
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights.骨肉瘤免疫微环境:细胞斗争与新的治疗见解
Front Immunol. 2025 Jun 4;16:1584450. doi: 10.3389/fimmu.2025.1584450. eCollection 2025.
6
Knowledge of Malignant Bone Tumors in Children Among Parents in Majmaah Region.麦加地区父母对儿童恶性骨肿瘤的了解情况。
J Pharm Bioallied Sci. 2025 May;17(Suppl 1):S873-S877. doi: 10.4103/jpbs.jpbs_1795_24. Epub 2025 Apr 29.
7
promotes the proliferation, migration, and invasion of osteosarcoma cells by increasing the intracellular iron content and expression.通过增加细胞内铁含量和表达来促进骨肉瘤细胞的增殖、迁移和侵袭。
Front Oncol. 2025 May 29;15:1567216. doi: 10.3389/fonc.2025.1567216. eCollection 2025.
8
Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma.组蛋白乙酰化调节剂的综合多组学分析确定ASH1L为骨肉瘤的一种新型侵袭性标志物。
Discov Oncol. 2025 Jun 12;16(1):1070. doi: 10.1007/s12672-025-02920-6.
9
Exploratory Analysis of Molecular Subtypes in Early-Stage Osteosarcoma: Identifying Resistance and Optimizing Therapy.早期骨肉瘤分子亚型的探索性分析:识别耐药性与优化治疗
Cancers (Basel). 2025 May 16;17(10):1677. doi: 10.3390/cancers17101677.
10
Evaluation of Indoleamine 2,3-Dioxygenase (IDO) Expression in Osteosarcoma: Insights From a 10-Year Retrospective Cohort.骨肉瘤中吲哚胺2,3-双加氧酶(IDO)表达的评估:来自一项10年回顾性队列研究的见解
Onco Targets Ther. 2025 Mar 17;18:367-377. doi: 10.2147/OTT.S494899. eCollection 2025.
Cell Mol Life Sci. 2021 Dec;78(23):7161-7183. doi: 10.1007/s00018-021-03966-9. Epub 2021 Oct 11.
4
Identification of a Novel Prognostic Gene Signature From the Immune Cell Infiltration Landscape of Osteosarcoma.从骨肉瘤免疫细胞浸润图谱中鉴定一种新的预后基因特征
Front Cell Dev Biol. 2021 Sep 6;9:718624. doi: 10.3389/fcell.2021.718624. eCollection 2021.
5
Screening a novel signature and predicting the immune landscape of metastatic osteosarcoma in children via immune-related lncRNAs.通过免疫相关长链非编码RNA筛选儿童转移性骨肉瘤的新型特征并预测其免疫格局。
Transl Pediatr. 2021 Jul;10(7):1851-1866. doi: 10.21037/tp-21-226.
6
A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.骨肉瘤肿瘤微环境中免疫浸润的综合分析。
Cancer Med. 2021 Aug;10(16):5696-5711. doi: 10.1002/cam4.4117. Epub 2021 Jul 13.
7
New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma.间充质干细胞的新视角:调控骨肉瘤的分子机制
J Bone Oncol. 2021 Jun 23;29:100372. doi: 10.1016/j.jbo.2021.100372. eCollection 2021 Aug.
8
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2 pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice.N-803(白细胞介素 15 超激动剂)与体外扩增自然杀伤细胞联合进行组合免疫疗法,显著增强了针对 GD2 小儿实体瘤的体外细胞毒性和异种移植免疫缺陷 NSG 小鼠的体内存活率。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-002267.
9
Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.过继性自然杀伤细胞免疫疗法治疗犬骨肉瘤
Front Vet Sci. 2021 Jun 7;8:672361. doi: 10.3389/fvets.2021.672361. eCollection 2021.
10
B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication.B细胞对抗肿瘤免疫反应的协调作用:细胞定位与通讯问题
Front Cell Dev Biol. 2021 Jun 7;9:678127. doi: 10.3389/fcell.2021.678127. eCollection 2021.